Aclaris Therapeutics, Inc. (ACRS)
Company Description
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States.
It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases.
The Contract Research segment offers laboratory services. The company develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis.
It develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an oral MK2 inhibitor for the treatment of pancreatic and metastatic breast cancer.
Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
| Country | United States |
| Founded | 2012 |
| IPO Date | Oct 7, 2015 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 100 |
| CEO | Dr. Douglas J. Manion Frcp(C), M.D. |
Contact Details
Address: 701 Lee Road, Suite 103 Wayne, Pennsylvania 19087 United States | |
| Phone | 484-324-7933 |
| Website | aclaristx.com |
Stock Details
| Ticker Symbol | ACRS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001557746 |
| CUSIP Number | 00461U105 |
| ISIN Number | US00461U1051 |
| Employer ID | 46-0571712 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Neal S. Walker D.O. | Co-Founder, Chief Executive Officer and Director |
| Frank Ruffo | Co-Founder, Chief Financial Officer and Treasurer |
| Dr. Joseph Monahan | Chief Scientific Officer |
| Dr. Douglas J. Manion Frcp(C), M.D. | President and Chief Operating Officer |
| Robert A. Doody Jr. | Vice President of Investor Relations |
| Matthew Rothman J.D. | General Counsel and Corporate Secretary |
| Dr. Jon Jacobsen Ph.D. | Senior Vice President of Chemistry |
| Dr. Paul S. Changelian Ph.D. | Senior Vice President of Biology |
| James Loerop | Chief Business Officer |
| Dr. Ian Anderson Ph.D. | Executive Vice President of Translational Research & Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 19, 2023 | 8-K | Current Report |
| Dec 11, 2023 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Dec 11, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 24, 2023 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2023 | 8-K | Current Report |
| Nov 6, 2023 | 10-Q | Quarterly Report |
| Nov 6, 2023 | 8-K | Current Report |
| Oct 23, 2023 | 144 | Filing |
| Sep 18, 2023 | 8-K | Current Report |
| Sep 5, 2023 | SC 13G | Statement of acquisition of beneficial ownership by individuals |